← All trials
NCT04610671
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 23, 2020
- Primary completion
- Nov 30, 2022
- Completion date
- Nov 30, 2022
- First posted
- Oct 30, 2020
- Last posted
- Nov 3, 2020
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of South FloridaLead sponsor
- University of South FloridaOverall official - principal investigator
- Cold Genesys, Inc.Collaborator
- Richard M. Shulze Family FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.